Your browser doesn't support javascript.
loading
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Jabbour, Elias; Sasaki, Koji; Short, Nicholas J; Ravandi, Farhad; Huang, Xuelin; Khoury, Joseph D; Kanagal-Shamanna, Rashmi; Jorgensen, Jeffrey; Khouri, Issa F; Kebriaei, Partow; Jain, Nitin; Alvarado, Yesid; Kadia, Tapan M; Paul, Shilpa; Garcia-Manero, Guillermo; Dabaja, Bouthaina S; Burger, Jan A; DiNardo, Courtney D; Daver, Naval A; Montalban-Bravo, Guillermo; Yilmaz, Musa; Ohanian, Maro; Ferrajoli, Alessandra; Jacob, Jovitta; Rostykus, Meagan; Garris, Rebecca; O'Brien, Susan; Kantarjian, Hagop M.
Afiliación
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jorgensen J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Khouri IF; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Paul S; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Burger JA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver NA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jacob J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rostykus M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garris R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • O'Brien S; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 127(12): 2025-2038, 2021 06 15.
Article en En | MEDLINE | ID: mdl-33740268
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Cancer Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Cancer Año: 2021 Tipo del documento: Article